Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 102

1.

Health Behaviours in Scaffold Use Risk Assessment Model - SURAM.

Bojar H, Silveira F, Rebelo M, Elżbieta C, Krzysztof C.

Ann Agric Environ Med. 2019 Mar 22;26(1):138-142. doi: 10.26444/aaem/100534. Epub 2019 Jan 3.

2.

Contamination of selected recreational areas in Lublin Province, Eastern Poland, by eggs of Toxocara spp., Ancylostoma spp. and Trichuris spp.

Bojar H, Kłapeć T.

Ann Agric Environ Med. 2018 Sep 25;25(3):460-463. doi: 10.26444/aaem/92252. Epub 2018 Aug 8.

3.

Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2.

Kleef R, Moss R, Szasz AM, Bohdjalian A, Bojar H, Bakacs T.

Integr Cancer Ther. 2018 Dec;17(4):1297-1303. doi: 10.1177/1534735418794867. Epub 2018 Sep 7.

4.

Tawny owl (Strix aluco) as a potential transmitter of Enterobacteriaceae epidemiologically relevant for forest service workers, nature protection service and ornithologists.

Grzywaczewski G, Kowalczyk-Pecka D, Cios S, Bojar W, Jankuszew A, Bojar H, Kolejko M.

Ann Agric Environ Med. 2017 Mar 31;24(1):62-65. doi: 10.5604/12321966.1230732.

5.

NEW ASPECTS REGARDING NEOADJUVANT RADIOCHEMOTHERAPY IN LOCALLY ADVANCED NONINFLAMMATORY BREAST CANCER AND PREDICTIVE FACTORS FOR A PATHOLOGIC COMPLETE REMISSION: IGCS-0016 Breast Cancer.

Matuschek C, Boelke E, Budach W, Speer V, Bojar H, Audretsch W, Nestle K.

Int J Gynecol Cancer. 2015 May;25 Suppl 1:1. No abstract available.

PMID:
25955892
6.

Preanalytical variables and performance of diagnostic RNA-based gene expression analysis in breast cancer.

Poremba C, Uhlendorff J, Pfitzner BM, Hennig G, Bohmann K, Bojar H, Krenn V, Brase JC, Haufe F, Averdick M, Dietel M, Kronenwett R, Denkert C.

Virchows Arch. 2014 Oct;465(4):409-17. doi: 10.1007/s00428-014-1652-0. Epub 2014 Sep 14.

7.

Increased CD44s and decreased CD44v6 RNA expression are associated with better survival in myxofibrosarcoma patients: a pilot study.

Matuschek C, Lehnhardt M, Gerber PA, Poremba C, Hamilton J, Lammering G, Orth K, Budach W, Bojar H, Bölke E, Peiper M.

Eur J Med Res. 2014 Feb 3;19:6. doi: 10.1186/2047-783X-19-6.

8.

Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer.

Darb-Esfahani S, Kronenwett R, von Minckwitz G, Denkert C, Gehrmann M, Rody A, Budczies J, Brase JC, Mehta MK, Bojar H, Ataseven B, Karn T, Weiss E, Zahm DM, Khandan F, Dietel M, Loibl S.

Br J Cancer. 2012 Nov 20;107(11):1892-900. doi: 10.1038/bjc.2012.475. Epub 2012 Oct 18.

9.

Long-term outcome after neoadjuvant radiochemotherapy in locally advanced noninflammatory breast cancer and predictive factors for a pathologic complete remission : results of a multivariate analysis.

Matuschek C, Bölke E, Roth SL, Orth K, Lang I, Bojar H, Janni JW, Audretsch W, Nestle-Kraemling C, Lammering G, Speer V, Gripp S, Gerber PA, Buhren BA, Sauer R, Peiper M, Schauer M, Dommach M, Struse-Soll K, Budach W.

Strahlenther Onkol. 2012 Sep;188(9):777-81. Epub 2012 Aug 11.

PMID:
22878547
10.
11.

A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors.

Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, Chen Z, Boehm D, Gebhard S, Petry I, Lebrecht A, Cadenas C, Marchan R, Stewart JD, Solbach C, Holmberg L, Edlund K, Kultima HG, Rody A, Berglund A, Lambe M, Isaksson A, Botling J, Karn T, Müller V, Gerhold-Ay A, Cotarelo C, Sebastian M, Kronenwett R, Bojar H, Lehr HA, Sahin U, Koelbl H, Gehrmann M, Micke P, Rahnenführer J, Hengstler JG.

Clin Cancer Res. 2012 May 1;18(9):2695-703. doi: 10.1158/1078-0432.CCR-11-2210. Epub 2012 Feb 20.

12.

Do insulin-like growth factor associated proteins qualify as a tumor marker? Results of a prospective study in 163 cancer patients.

Matuschek C, Rudoy M, Peiper M, Gerber PA, Hoff NP, Buhren BA, Flehmig B, Budach W, Knoefel WT, Bojar H, Prisack HB, Steinbach G, Shukla V, Schwarz A, Kammers K, Erhardt A, Scherer A, Bölke E, Schauer M.

Eur J Med Res. 2011 Oct 10;16(10):451-6.

13.

Methylated APC and GSTP1 genes in serum DNA correlate with the presence of circulating blood tumor cells and are associated with a more aggressive and advanced breast cancer disease.

Matuschek C, Bölke E, Lammering G, Gerber PA, Peiper M, Budach W, Taskin H, Prisack HB, Schieren G, Orth K, Bojar H.

Eur J Med Res. 2010;15:277-86.

14.

Retrospective study of neoadjuvant versus adjuvant radiochemotherapy in locally advanced noninflammatory breast cancer : survival advantage in cT2 category by neoadjuvant radiochemotherapy.

Roth SL, Audretsch W, Bojar H, Lang I, Willers R, Budach W.

Strahlenther Onkol. 2010 Jun;186(6):299-306. doi: 10.1007/s00066-010-2143-0. Epub 2010 May 21.

PMID:
20495968
15.

[Nitazoxanide ("Alinia")--a promising antiparasitic drug].

Bojar H, Knap JP.

Wiad Parazytol. 2010;56(1):11-8. Review. Polish.

PMID:
20450003
16.

ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction.

Brase JC, Schmidt M, Fischbach T, Sültmann H, Bojar H, Koelbl H, Hellwig B, Rahnenführer J, Hengstler JG, Gehrmann MC.

Clin Cancer Res. 2010 Apr 15;16(8):2391-401. doi: 10.1158/1078-0432.CCR-09-2471. Epub 2010 Apr 6.

17.

Radiation therapy and tamoxifen after breast-conserving surgery: updated results of a 2 x 2 randomised clinical trial in patients with low risk of recurrence.

Winzer KJ, Sauerbrei W, Braun M, Liersch T, Dunst J, Guski H, Schumacher M; German Breast Cancer Study Group (GBSG).

Eur J Cancer. 2010 Jan;46(1):95-101. doi: 10.1016/j.ejca.2009.10.007.

PMID:
19879131
18.

Gene expression of circulating tumour cells in breast cancer patients.

Bölke E, Orth K, Gerber PA, Lammering G, Mota R, Peiper M, Matuschek C, Budach W, Rusnak E, Shaikh S, Dogan B, Prisack HB, Bojar H.

Eur J Med Res. 2009 Sep 28;14(10):426-32.

19.

Gene expression of circulating tumour cells and its correlation with tumour stage in breast cancer patients.

Bölke E, Orth K, Gerber PA, Lammering G, Mota R, Peiper M, Matuschek C, Budach W, Rusnak E, Shaikh S, Dogan B, Prisack HB, Bojar H.

Eur J Med Res. 2009 Aug 12;14(8):359-63.

20.

Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.

Pagani O, Gelber S, Simoncini E, Castiglione-Gertsch M, Price KN, Gelber RD, Holmberg SB, Crivellari D, Collins J, Lindtner J, Thürlimann B, Fey MF, Murray E, Forbes JF, Coates AS, Goldhirsch A; International Breast Cancer Study Group.

Breast Cancer Res Treat. 2009 Aug;116(3):491-500. doi: 10.1007/s10549-008-0225-9. Epub 2008 Oct 25.

Supplemental Content

Loading ...
Support Center